Linden Advisors’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Linden Advisors’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-97,271	Closed	-$970K	–	842
2021 Q1	$970K	Sell	97,271 -2,729	-3%	-$29.1K	0.01%	517
2020 Q4	$1.08M	Hold	100,000	–	–	0.01%	373
2020 Q3	$1.04M	Hold	100,000	–	–	0.01%	252
2020 Q2	$1M	Buy	+100,000	New	+$995K	0.02%	188

Other funds holding STLN

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

KLC

Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Linden Advisors's STLN Position: Q2 2021 in Review

Linden Advisors sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q2 2021, closing a stake of 97,271 shares — an estimated $970K sold.

Linden Advisors first reported a position in STLN in Q2 2020 and held it in 4 quarters. The position peaked at $1.08M in Q4 2020. 53 funds tracked by Wall St. Rank hold STLN as of Q2 2021.

Linden Advisors reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Linden Advisors sold 97,271 Starling Oncology Institute, Inc. Common Stock shares in Q2 2021, an estimated $970K.
Linden Advisors first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2020 and held it in 4 quarters.
Linden Advisors's Starling Oncology Institute, Inc. Common Stock position peaked at $1.08M in Q4 2020.
53 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2021.

Based on Linden Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.